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Evaluation of the relative merits of medical versus surgical management of vesicoureteral reﬂux (VUR) has been limited by the few
prospective studies comparing these strategies. Among those trials that have been reported, the only consistent positive ﬁnding has
been that incidence of febrile UTI is lower among children undergoing surgical treatment in comparison with medical treatment.
StudieshavenotfoundsigniﬁcantdiﬀerencesinoverallincidenceofUTI,orinratesofnewrenalscarringorprogressionofexisting
scarring. It is likely that there is a subset of children with VUR who do beneﬁt from aggressive treatment of their VUR, but we are
not yet able to fully determine which children these are. It is hoped that future research will further clarify which treatments are
useful in which children.
Copyright © 2008 Caleb P. Nelson. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Urinary tract infection (UTI) is one of the most common
seriousbacterialinfectionsinchildren.Cumulativeincidence
is 1-2% among boys and 3–7% among girls, and between
70000 to 180000 of the annual US birth cohort will have
a UTI by the age of 6 [1]. Roughly 30–50% of children
with UTI are found to have vesicoureteral reﬂux (VUR, the
retrograde ﬂow of urine from the bladder into the ureter
and/or kidney). Because VUR (particularly when coexistent
with UTI) has been associated with increased risk of renal
scarring, proteinuria, hypertension, eclampsia, and end-
stage renal disease (ESRD) [2], children with UTI typically
undergo diagnostic evaluation for and treatment of VUR.
In addition to its association with UTI, VUR is also a
highly genetic condition, displaying an autosomal dominant
transmission pattern, with variable penetrance. VUR may
occur in up to 66% of the oﬀspring of VUR patients [3], and
theprevalenceofVURamongsiblingsofindexVURpatients
is approximately 32% [4].
It has long been appreciated that there is an associa-
tion between recurrent UTI, VUR and renal parenchymal
scarring [5]. The traditional paradigm holds that once
pathogenic bacteria establish infection in the bladder, the
presence of VUR allows these bacteria to gain access to the
upper tracts, invading the renal parenchyma and producing
clinical acute pyelonephritis [6]. The resulting inﬂammatory
cascade is presumed to result in tissue damage, ﬁbrosis, and
scarring in susceptible individuals.
In general, most management strategies for VUR have
sought to address and defeat this process at various points
along the pathogenic sequence. Medical management with
antimicrobial prophylaxis seeks to maintain sterile urine,
rendering the VUR itself relatively harmless, since there are
nobacteriapresenttoreachandinvadethekidney.Antireﬂux
surgery (ARS), in contrast, reconﬁgures the ureterovesical
junction anatomy to block access to the upper tracts, so that
any episodes of cystitis that do occur cannot progress to
pyelonephritis.
However, this model has been called into question in
recent years by data that challenges many of the assumptions
of the VUR paradigm. Long-term studies show that renal
scarring can occur in children without VUR, and that renal
scarring is not common in children with even high degrees
of reﬂux [7, 8]. Rushton et al. noted that new renal scars are
formed less frequently after acute pyelonephritis in kidneys
with VUR than those without VUR [9], and other studies
have supported these ﬁndings to some extent [10]. End-
stage renal disease and transplant registries maintained since
the 1960’s have not demonstrated the reduction in the2 Advances in Urology
proportion of cases attributable to VUR that one would
expect, if the management strategies instituted since that
time were having a signiﬁcant impact on rates of renal
scarring and renal insuﬃciency [7, 11].
As we will see below, it has been diﬃcult to demonstrate
that current management strategies for VUR result in
measurably improved outcomes. Since these management
strategies are based on assumptions about the pathophysi-
ology of UTI, VUR, and renal scarring, if such assumptions
are incorrect then it should not surprise us that our
interventions seem to have little or no eﬀect.
2. MEDICAL MANAGEMENT
The use of antimicrobials to reduce recurrent and/or chronic
UTI’s dates back to the 1940’s and 50’s, and is the mainstay
of initial management in children diagnosed with VUR.
Based on the perception that antimicrobial prophylaxis is
safe, eﬀective, and easily tolerated, generations of children
with VUR have spent years undergoing this treatment
while awaiting the spontaneous resolution of their VUR.
The classic studies of Smellie et al. form much of the
basis for prophylaxis as a management tool [2, 5, 12].
In their numerous series, the Smellie group made semi-
nal observations regarding the associations between VUR,
UTI, and negative renal outcomes including scarring and
decreased renal growth, and developed hypotheses regarding
the apparent beneﬁts of antimicrobial prophylaxis in chil-
dren with VUR. They noted that children on continuous
antimicrobial prophylaxis seemed to have fewer recurrent
UTI than those on intermittent antibiotics, that children
who stopped antibiotics seemed to be prone to recurrence
shortly thereafter, and that increasing number of infections
wasassociatedwithincreasedriskofrenalscarring.Although
groundbreaking, these data were based on nonrandomized,
retrospective reviews, and thus do not adequately control for
confounding factors and bias.
As a consequence, antimicrobial prophylaxis lacks basic
evidence of eﬃcacy in prevention of either UTI or renal
scarring. Three randomized controlled trials comparing
antimicrobial prophylaxis with no treatment (surveillance
only) have been reported [13–15], and one of these was
published in conference proceedings only [14]. None of the
trials found signiﬁcant diﬀerences in rates of UTI or renal
scarring in treatment versus nontreatment groups. In the
most recent study [15], subjects were kept on antimicrobial
prophylaxis or no treatment for 2 years, and then were
followed oﬀ medication for an additional 2 years. There were
no diﬀerences in UTI rates either at the 2-year or 4-year
mark. A recent population-based study using administrative
data in a group of 611 children with UTI (27% of whom had
VUR) found that the use of antimicrobial prophylaxis was
not associated with decrease in risk of recurrent UTI [16].
Althougheachofthesestudieshasmethodologicalproblems,
the failure of any of them to ﬁnd any eﬀect of antimicrobial
prophylaxis in preventing UTI suggests that the eﬀect, if any,
is likely to be very small. This, in turn, suggests that large
number of children need to be treated for any single child to
experience the beneﬁts of prophylaxis.
3. SURGICAL MANAGEMENT
Since the initial report of surgical correction of VUR
by Hutch in 1952 [17], numerous techniques have been
developed to accomplish the basic goals of ARS, that is,
prevention of retrograde ﬂow of urine into the ureter
and kidney. In fact, many of the leading ﬁgures in the
development of the specialty of pediatric urology made their
names largely through their accomplishments in perfecting
ARS techniques. Today, in expert hands, the success rate
of straightforward ARS approaches 100%, such that some
surgeons no longer bother with post-ARS cystography to
conﬁrm VUR resolution [18–20].
The extraordinary success of modern ARS might lead
one to assume that there is little room left for technical
innovation in this ﬁeld. However, investigators have long
sought a less invasive way to correct VUR. In 1981, the
ﬁrst injection technique was reported by Matouschek using
polytetraﬂuoroethylene (PTFE; Teﬂon) paste [21]. Concern
over migration of PTFE particles to distant body sites [22]
limited the popularity of this bulking agent in the United
States, but in 1995, a Swedish group reported development
of a dextranomer copolymer/hyaluronic acid gel for use as
an injectable bulking agent (DX/HA; Deﬂux) [23]. The FDA
approved Deﬂux for correction of VUR in 2001, and since
then its use has increased signiﬁcantly in many parts of the
US [24] , with reported VUR resolution rates of 68–89%
[25–28].
To our knowledge, there have not been any prospective
trials of surgical management compared with observation
in children with VUR. Therefore, we simply do not know if
ARS is superior to surveillance alone in prevention of UTI or
renal scarring. Because active management of VUR (either
with antibiotics or surgery) is considered standard of care,
it is diﬃcult to ﬁnd patients who have truly been given no
treatment for their VUR, even in a retrospective review.
4. COMPARISON OF SURGICAL VERSUS
MEDICAL MANAGEMENT
Comparison of medical treatment with surgical treatment
for VUR is challenging because the diﬀerent studies have
used various outcome measures, and even studies using
similar outcome measures may be diﬃcult to compare
due to diﬀering deﬁnitions of similar outcomes. Reported
outcomes in many studies include postoperative incidence
of any UTI, incidence of febrile UTI (presumed in most
cases to be equivalent to pyelonephritis), and renal cortical
abnormalities (scarring).
In a recent metaanalysis of clinical trials, Hodson et
al. identiﬁed seven randomized controlled trials comparing
surgical and medical management [29–35] and summarized
their results [36].
4.1. AnyUTI
There was no diﬀerence in incidence of any UTI between
treatment groups, with incidence of 29–42% in antibiotic
only group and 25–40% in the surgical group [29–35]. Thus,Caleb P. Nelson 3
surgical treatment of VUR does not seem to reduce the rate
of UTI overall.
4.2. FebrileUTI
Reported in only 2 studies, this is the only outcome where
signiﬁcant diﬀerences in outcomes have been observed
between treatments [31, 37]. The surgical group had sig-
niﬁcantly fewer febrile UTI’s in short-term and long-term
followup[32],withrelativeriskoffebrileUTIduringtheﬁrst
5 years of 0.43 (95% CI: 0.27–0.70).
4.3. Renalscarring
In the ﬁve studies that assessed renal parenchymal abnor-
malities using IVP criteria [29–31, 33, 38], there were no
signiﬁcant diﬀerences noted between surgical and medical
groups. The majority of these studies assessed renal abnor-
malities using IVP. In the two studies that reported DMSA
renal scintigraphy [35, 39], there was no diﬀerence in either
progression of existing scars or development of new scars.
4.4. Futuredirections
There is little strong evidence supporting the hypothesis
that early detection and treatment of VUR is of any beneﬁt,
primarily because it has been so diﬃcult to demonstrate any
beneﬁt from the available therapies. Perhaps the one ﬁrm
conclusionwecandrawfromtheliteraturedescribedaboveis
that, among children with VUR who have had breakthrough
febrile UTI’s while on antimicrobial prophylaxis, ARS is
an appropriate therapy that can be expected to reduce
the incidence of such febrile episodes. However, neither
prophylaxis nor ARS can be reliably stated to reduce the risk
ofneworprogressiverenalscarring,althoughitisprevention
of this outcome that is widely assumed to be the most
important beneﬁt of VUR treatment.
It is plausible that, while treatment of VUR may reduce
the risk of negative outcomes in a small subset of VUR
patients, the number needed to be treated (in order to realize
those beneﬁts); it may be so high as to make the intervention
unjustiﬁed for the overall VUR population. For this reason,
ongoing research into biomarkers that will indicate those
at highest risk for recurrent infection and progressive renal
damage is crucial; such biomarkers would allow us to narrow
the ﬁeld of candidates for medical or surgical treatment
to those most likely to beneﬁt, and allow the larger VUR
population to escape the morbidity and bother associated
with these treatments.
Finally, there has been much recent discussion about
whether the availability of endoscopic ARS should alter the
indications for ARS. Suggestions have begun to appear in the
literatureandatnationalmeetingsthatendoscopictreatment
should be utilized as initial therapy for patients diagnosed
with VUR. Advocates argue that immediate endoscopic
therapy is preferable to antimicrobial prophylaxis in children
just diagnosed with VUR [40]. Current standards of care
do not yet embrace such early treatment: Khoury and Bagli
state in their textbook chapter that “the indications for
correction of reﬂux should remain unchanged regardless” of
technique [41]. Furthermore, the data shown above make it
clear that immediate ARS (using any method) makes little
sense: the only demonstrated beneﬁt of ARS is the reduction
in incidence of recurrent febrile UTI, and a majority of
newly diagnosed patients with VUR (except those with
high-grade VUR) will never experience a recurrent febrile
UTI, regardless of treatment choice [13, 16]. Therefore, an
algorithm that directs all newly diagnosed VUR patients
into immediate surgical treatment (even if it is the “low
morbidity” of endoscopic ARS) is destined to overtreat large
numbers of children for whom there will not be measurable
beneﬁts.
Ongoing clinical studies will hopefully clarify some of
the glaring shortcomings in our evidence base. The NIDDK-
funded RIVUR study is a randomized trial of antimicrobial
prophylaxis versus placebo in children with VUR and UTI
[42]. Each subject is followed for 2 years during which
incidence of UTI and renal scarring by DMSA criteria will be
tracked. DMSA scans will be obtained at study entry, 1 year,
and 2 years. Weaknesses of the study will include the broad
range of subjects (intended to increase generalizability),
including boys and girls, VUR Grade I-IV, ages 2 months
to 5 years, and inclusion of trained and nontoilet trained
children, with or without voiding dysfunction. Although the
2-yeartimeframeisshort,thislargestudy(targetsamplen =
600) will provide us with superb data regarding risk of UTI
and renal scarring in children with VUR in the short term,
as well as demonstrate whether antimicrobial prophylaxis is
eﬀective in preventing either UTI or scarring. Other studies
assessing the utility of ARS in various clinical scenarios
are desperately needed. Until such studies are complete,
clinicians who treat children with VUR will continue to rely
on clinical judgment, experience, and intuition to manage
their young patients.
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